Polyene Phosphatidylcholine Injection for the Treatment of Perioperative Liver Injury With Laparoscopic Hemihepatectomy in Hepatocellular Carcinoma: a Multicenter Randomized Controlled Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hemihepatectomy for hepatocellular carcinoma were compared.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection

• Those who plan to undergo right or left hemi-liver resection

• During the operation, the Pringle method was used to block the first hepatic portal. Each block lasted for no more than 15 minutes, and the blocking procedure was performed 2 to 4 times.

• Age: 18 - 70 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg/m2

• Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III

• Preoperative ICG R15 was less than 10%, and the residual liver volume was more than 40% of the standard liver volume

• A single HCC (hepatocellular carcinoma), with a tumor diameter less than 10 cm, without distant metastasis or invasion of the portal vein system

• Preoperative ALT was less than 2 times the upper limit of normal

• Before being enrolled in the study, the patient had no history of any other treatments, such as portal vein embolization, TACE or systemic anti-tumor drug therapy.

⁃ No liver-damaging treatment drugs were used within two weeks prior to enrollment.

Locations
Other Locations
China
Anhui Provincial Hospital
RECRUITING
Hefei
Contact Information
Primary
Lianxin Liu
liulx@ustc.edu.cn
0551-96512
Time Frame
Start Date: 2025-08-30
Estimated Completion Date: 2026-03-31
Participants
Target number of participants: 96
Treatments
Experimental: Experimental group
Active_comparator: control group
Related Therapeutic Areas
Sponsors
Collaborators: First Affiliated Hospital of Wannan Medical College, The Second Hospital of Anhui Medical University, The First Affiliated Hospital of Bengbu Medical University, The First Affiliated Hospital of Anhui Medical University
Leads: Anhui Provincial Hospital

This content was sourced from clinicaltrials.gov